HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
The Week

Alnylam, Inceptive ink AI deal potentially worth $2B

The RNA-focused drugmaker says Inceptive's tools will help prioritize the best development options as well as speed up the research process.

By BioPharma Dive · Jun 4, 2026 · via BioPharma Dive
Alnylam, Inceptive ink AI deal potentially worth $2B

Image: BioPharma Dive

This is an aggregated industry headline. Read the full story at BioPharma Dive →

Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
It's unanimous: SCOTUS agrees with Hikma in 'skinny label' case vs. Amarin
The WeekFiercePharma ↗
It's unanimous: SCOTUS agrees with Hikma in 'skinny label' case vs. Amarin
With a resounding unanimous vote, the U.S. Supreme Court has sided with Hikma Pharmaceuticals, ruling that its…
Jun 5, 2026
At first public hearing for FDA's CNPV program, industry support meets 'deep concern' from experts
The WeekFierceBiotech ↗
At first public hearing for FDA's CNPV program, industry support meets 'deep concern' from experts
On Thursday, the public had the first chance to air their grievances about the FDA's controversial Commissione…
Jun 5, 2026
White House Targets NIH Job Protections in Research Oversight Shake-Up
The WeekBriefing
White House Targets NIH Job Protections in Research Oversight Shake-Up
The Trump administration plans to strip job protections from around 8,000 NIH officials overseeing research gr…
Jun 5, 2026